sweet sensors final presentation

*GlucoSentient, Inc.

Gluco = GlucoseSentient = Responsive to, perceptive or aware

Direct Read Out of Target

Concentration!

Patient Samples

(Blood/Saliva/ Urine )

Personal Glucose Meter

Drug/Targets

ofinterest

*Diagnostics platform leveraging personal glucose meters:

Therapeutic drug monitoring (TDM)

Clinical trial companion diagnostics

Medical diagnosis of many diseases

Environmental detection of contaminants

~100 GOOTB connections

*I-Corps Video

*Diabetes patients were our initial target market

*Existing glucose meter + need to measure HbA1c

*Key value propositions

*Low cost

*Home testing

*Already have PGM

*Large market

*Patient population is huge

More frequent tests and better diabetes management

Total available market = $1.2

billion

Serviceable Available Market = $600 million

Target market = $120 million

*Initial Hypotheses

Business Model Canvas #1

Diabetics

Sweet SensorsYi Lu, Tian LanNeil KaneChris Sorensen

Clinicians (in rural area)

Triage nurses

Pre-diabetics

Product supports

Patient network/community

Retailers (Walgreen)

Online vendors (Amazon)

Direct sales

Disposable test kit (used repeatedly on a regular basis)

At home

Convenient

Less exposure to infectious diseases in the hospital

Cheaper

More frequent

Better indicator of health (diabetic management)

Conferences

Product R&D

QC

Marketing

IP

Personnel

Glucose monitor manufacturers

Kit manufacturers

Reagent suppliers

Reagents

Manufacture

Licensing

FDA certification?

10-11--2011

*Got out of the building (GOOTB)

The best test is one where the result

affects the behavior. Find a

test where immediate results

have value.

(I) spent a lot of time, money

looking at this (HbA1c) market for

LifeScan – stay away.

*Got out of the building (GOOTB)

“You might even have a flexible Drugs of Abuse

Analyzer “Bank” which is actually a rack which holds a number of small

individual analyzers.”

“The “Holy Grail” now is matching drug dosages to individual patients based on a wide range of factors (age, weight, gender, ethnicity, body chemistry, etc.)So ONE DOSE DOES NOT FIT ALL”

*What we have found….

…….became our value propositions

* Immediacy

* Inexpensive/cost savings

* Multiple tests

* Short and inexpensive development cycles

*We learned that for HbA1c…(is not the right market)

*Home monitoring of HbA1c does not meet immediacy requirement

*Large effort is necessary to promote the usage of home HbA1c test kit in the US

*Competition from product from Bayer

*Large regulatory hurdle

* One market that meets all the value propositions is drug monitoring during clinical trials and after the market


Pivoted

to therapeutic

drug

monitorin

g

Diabetics



Pre-diabetics

Product support



Medical Products Distributors


Conferences

Product R&D

QC Marketing

IP Personnel

Glucose monitor manufacturers- Abbott?

Kit manufacturers

Reagent suppliers

Reagents

Manufacturing

Licensing

Convenient

Out of clinic

Cheaper

More frequent

FDA approval for in vitro diagnostics


KOL

Immediacy

Food safety and security related

10-25-2011

Reimbursement strategy

Drug monitoring

Pharmaceutical Cos

Sponsored development or JDALicensing

Pivoted

to therapeutic

drug

monitorin

g


Sweet SensorsYi Lu, Tian Lan, Brian WongNeil KaneChris Sorensen

One to one

Conferences

R&D

QC

IP

Personnel

Pharmaceutical companies

R&D

Licensing

Convenient monitoring and safer dosage

Immediacy

11-01-2011

Pharmaceutical companies for Therapeutic Drug Monitoring (TDM)

Pharmaceutical Cos

Sales (to pharmaceutical companies)

Pharmaceutical Cos

Long termGlucometer/strip manufacturer

Exclusive

*We talked to a major pharmaceutical company several times and learned…. (values for pharmas)

*Better drug monitoring reduces the costs of drug development

*“One-drug-for-all” is gone; new drugs are more likely to be effective for certain patients at certain dosage.

*They are willing to provide financial support

*They only want to buy the final products

*Therefore we need to find partners

*Partners

Added value for meter manufacturers

Low cost, fast monitoring improves

clinical trials for pharmaceutical

Meter engineerin

gStrip

designFDA

approval

Provide the targets

Key customersKey market knowledge

GlucoSentient, Inc. Glucose meter companies




Direct

Conferences

R&D

IP

Personnel


R&D

Licensing


Immediate results

11-15-2011

Pharmaceutical Cos

Product Sales

Long term

Diagnostics companies

Contract research organizations


Diagnostic companies

Contract research organizationsInvestors

Publicity

Inexpensive

Simple

Insurance Reimbursement

Robust/extensible

Licensing?

Glucometer mfr

Strip mfr

Pharmaceutical Cos

*Competitive Analysis

Time to obtain the test results

Develo

pm

en

t co

sts

Conventional Lab Test

POC tests

Our Technology

Total available market ~$20 billion

Serviceable available Market ~ 2 billion

Target market ~$645 million

Axis Shield (clinic based, fluidics tests for HbA1c, CRP…)acquired Alere for $366 million (10/2011)

Claros (sensitive fluidics device for HIV detection using antibodies) acquired for $46 million by OPKO (11/2011)

*Market size (POC test)

Source: Point of Care Testing, Biophoenix 2010

Source: American Association for Clinical Chemistry

*Next Steps

*Pitch to other pharmaceutical and diagnostic companies

*Develop prototype for the BEST targets in therapeutic drug monitoring to demonstrate our technology

*Apply SBIRs to reduce technical risks

*License the technology from the University of Illinois

*Move into the Research Park at the University of Illinois through the I-Start program

Diabetics




Triage nurses

Pre-diabetics

Product supports




Direct sales


At home

Convenient


Cheaper

More frequent


IP

Personnel

Reagents

Manufacture

Licensing

FDA certification?


Kit manufacturers

Reagent suppliers

Conferences

Product R&D

QC

Marketing

* Diabetics




Triage nurses

Pre-diabetics

Product supports




Direct sales




Kit manufacturers

Reagent suppliers

Reagents

Manufacture

Licensing

Convenient

At home


Cheaper

More frequent


Conferences

Product R&D

QC Marketing


IP Personnel

KOL

* Diabetics




Pre-diabetics

Product supports







Kit manufacturers

Reagent suppliers

Reagents

Manufacture

Licensing

Convenient

At home


Cheaper

More frequent


Immediacy


10-18-2011

Conferences

Product R&D

QC Marketing


IP Personnel

KOL

* Diabetics




Pre-diabetics

Product support





Conferences

Product R&D

QC Marketing

IP Personnel


Kit manufacturers

Reagent suppliers

Convenient

Out of clinic

Cheaper

More frequent


KOL

Immediacy


10-25-2011


Drug monitoring

Pharmaceutical Cos


Reagents

Manufacture

Licensing


* Diabetics




Pre-diabetics

Product support





Conferences

Product R&D

QC Marketing

IP Personnel


Kit manufacturers

Reagent suppliers

Convenient

Out of clinic

Cheaper

More frequent


KOL

Immediacy


10-25-2011


Drug monitoring

Pharmaceutical Cos


Reagents

Manufacture

Licensing


Pivoted

to therapeutic

drug

monitorin

g

*


Business Model Canvas #5b

One to one

Conferences

R&D

QC

IP

Personnel


R&D

Licensing


Immediacy

11-01-2011


Pharmaceutical Cos


Pharmaceutical Cos


Exclusive

*



One to one

Conferences

R&D

QC

IP

Personnel


R&D

Licensing


Immediacy

11-01-2011

Pharmaceutical Cos


Pharmaceutical Cos


Exclusive

Contract research organization


Glucometer/strip manufacturer

Diagnostic company

Contract research organization

Diagnostics companies

*


Business Model Canvas # 7 w/changes

Direct

Conferences

R&D

QC

IP

Personnel


R&D

Licensing


11-08-2011

Pharmaceutical Cos

Product Sales

Pharmaceutical Cos


ExclusiveDiagnostics companies



Glucometer/strip manufacturer



Investors

Publicity

Inexpensive

Simple


Robust/extensible

Licensing?

Glucometer mfr

Strip mfr

Immediacy

*


Business Model Canvas # 8

Direct

Conferences

R&D


R&D

Licensing


Immediate results

11-15-2011

Pharmaceutical Cos

Product Sales

Long termDiagnostics companies





Publicity

Inexpensive

Simple


Robust/extensible

Licensing?

Glucometer mfr

Strip mfr

IP

Personnel

Pharmaceutical Cos

Investors

*Acknowledgements

* NSF I-Corps program

* The I-Corps teaching team

*UIUC tech transfer terms

*Partners

GlucoSentient

• Added value for meter manufacturers

• Low cost, fast monitoring improves clinical trials

Glucose meter manufacturer• Meter engineering• Strip design• FDA approval

Pharmaceutical / diagnostic companies• Provide the target

of interest• Key customers• Key market

knowledge

sweet sensors final presentation

Education

large market

thishba1c market

pharmaceutical companies

initial target market

test results

pgm total available

better drug monitoring

best test